Novel therapeutic target identification by next generation sequencing mutation detection

Most of cancers result from accumulation of multiple genetic alterations that lead to dysfunction of cancer-related genes. These genetic alterations are important diagnostic, prognostic, and predictive biologic markers.

Next generation sequencing technologies permit deep sequencing of hundreds of cancer genes concurrently to identify mutations, some of whom are most likely to be driver mutations.

This test can provide important individual information regarding tumor development and progression, and a more reliable prediction of personalized cancer therapies.

Identification of driver mutations in brain cancer will assist in finding novel targets for drug development and serve basis for personalized treatment of brain cancer.